Boston, MA 05/09/2014 (wallstreetpr) – STERIS Corp (NYSE:STE) enjoyed an upward rally on higher volume on Thursday after it reported its fourth quarter and fiscal year results. The company has been able to beat the analysts’ projection both in terms of revenue and EPS in its fourth quarter.
Fourth Quarter And Full Year Results
The healthcare, pharmaceutical and research company’s fourth quarter revenue increased 8.7% to $465.3 million that exceeds the analysts’ estimates by $9.11 million. The revenue growth includes 7% growth in organic volume, a 1.6% improvement from acquisitions and a 30 basis point growth in pricing. In segmentwise revenue, healthcare reported the maximum growth of 11% at $352 million, followed by Isomedix that reported an increase of almost 8% to $49.4 million. Lifesciences contributed $63.7 million in revenue, denoting a fall of 1.6% year-over-year. The company’s operating income during the reported quarter fell 8.4% to $59.6 million, while its earnings per share came in at $0.91 per share, beating the analysts’ estimate of $0.86.
For the full year, STERIS Corp (NYSE:STE)’s revenue increased 8% to $1.62 billion, while its operating income fell 14.8% to $206.8 million. The earnings per share for the year stood at $2.17 per share.
FY15 Guidance
STERIS Corp (NYSE:STE) issued guidance for the year exceeding the forecast by the analysts. The company expects the revenue for the fiscal year 2015 to come in the range of $1.86-$1.90 billion, indicating a 15-17% growth from the current period. At the same time, the company expects earnings per share to be in between $2.78-$2.91 per share for the full fiscal year, against the analysts’ consensus of $2.76 per share. In the meanwhile, Steris projects the growth in the Healthcare segment in between 21-23% and by mid-single digits in Isomedix and Life Sciences. The company projects free cash flow at $135 million and capex at $95 million for the financial year 2015.
